Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
[en] BACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens. METHODS: For this retrospective study, we selected HIV-infected patients with suppressed viral load who fitted in one of the two groups below: First group (TDF/TDF): Patients treated continuously with TDF-based regimens. Second group (TDF/TAF): Patients treated with TDF-regimens during at least 6 months then switched to TAF-regimens while maintaining other drugs unchanged. Available data included date of birth, gender, ethnicity, lymphocyte T CD4(+) count, weight, height, blood pressure, current/ex/non-smoker, diabetes mellitus, familial cardiovascular event, lipid profile, duration and nature of antiretroviral therapy. Lipid parameters, weight and calculated cardiovascular risk using 5-year reduced DAD score algorithm [Friis-Møller et al. in Eur J Cardiovasc Prev Rehabil 17:491-501, 2010] were analyzed in each groups. RESULTS: Switching from TDF to TAF resulted in a significant increase in triglycerides levels, total cholesterol and HDL cholesterol. LDL cholesterol and total cholesterol/HDL ratio did not show significant changes. Calculated cardiovascular risk increased after switch from TDF- to TAF-based therapy. CONCLUSIONS: Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile should be included in the reflection to propose the most appropriate and tailored ARV treatment.
Disciplines :
Immunology & infectious disease
Author, co-author :
Plum, Pierre-Emmanuel; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Maes, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Service des Informations Médico-économiques > Appui à la Recherche Clinique et Biostatistique
Sauvage, Anne-Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine interne > Maladies infectieuses
Frippiat, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des Maladies infectieuses
Meuris, Christelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Uurlings, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Lecomte, Marianne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Léonard, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques
Fombellida, Karine; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Vaira, Dolores ; Centre Hospitalier Universitaire de Liège - CHU > Laboratoire > Laboratoire de référence SIDA
Moutschen, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Darcis, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501. 10.1097/HJR.0b013e328336a150. DOI: 10.1097/HJR.0b013e328336a150
Collaboration ATC. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–56. 10.1016/S2352-3018(17)30066-8. DOI: 10.1016/S2352-3018(17)30066-8
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33. 10.1016/S0140-6736(13)61809-7. DOI: 10.1016/S0140-6736(13)61809-7
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–6. 10.1093/cid/cir627. DOI: 10.1093/cid/cir627
Gagliardini R, Fabbiani M, Colafigli M, D’Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017;29(5):299–307. 10.1080/1120009X.2016.1269040. DOI: 10.1080/1120009X.2016.1269040
Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. 10.1097/01.qai.0000233310.90484.16. DOI: 10.1097/01.qai.0000233310.90484.16
Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte A, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A: D Study. AIDS. 2010;24(10):1537–48. 10.1097/QAD.0b013e32833a0918. DOI: 10.1097/QAD.0b013e32833a0918
Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55(2):262–70. 10.1097/QAI.0b013e3181e9be6b. DOI: 10.1097/QAI.0b013e3181e9be6b
Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, Lambert JS, Muldoon E, Feeney E, Mallon PW, Tinago W. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34(8):1161–70. 10.1097/QAD.0000000000002541. DOI: 10.1097/QAD.0000000000002541
De Voeght A, Martens H, Renard C, Vaira D, Debruche M, Simonet J, Geenen V, Moutschen M, Darcis G. Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium. PLoS ONE. 2017;12(10): e0185761. 10.1371/journal.pone.0185761. DOI: 10.1371/journal.pone.0185761
Darcis G, Maes N, Pasternak AO, Sauvage AS, Frippiat F, Meuris C, Uurlings F, Lecomte M, Léonard P, Elmoussaoui M, Fombellida K, Vaira D, Moutschen M. Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination antiretroviral therapy. Antimicrob Agents Chemother. 2020;64(3):e01902-e1919. 10.1128/AAC.01902-19. DOI: 10.1128/AAC.01902-19
Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17(1):551. 10.1186/s12879-017-2626-z. DOI: 10.1186/s12879-017-2626-z
Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074–81. 10.1086/521935. DOI: 10.1086/521935
Savès M, Chêne G, Ducimetière P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets JB, Reynes J, Bingham A, Raffi F. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37(2):292–8. 10.1086/375844. DOI: 10.1086/375844
Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, DeWit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35. 10.1056/NEJMoa062744. DOI: 10.1056/NEJMoa062744
Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86(1):27–31. 10.1016/0002-9343(89)90225-8. DOI: 10.1016/0002-9343(89)90225-8
Souza SJ, Luzia LA, Santos SS, Rondó PH. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras. 2013;59(2):186–98. 10.1016/j.ramb.2012.11.003. DOI: 10.1016/j.ramb.2012.11.003
Hanna DB, Ramaswamy C, Kaplan RC, Kizer JR, Anastos K, Daskalakis D, Zimmerman R, Braunstein SL. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001–2012. Clin Infect Dis. 2016;63(8):1122–9. 10.1093/cid/ciw470. DOI: 10.1093/cid/ciw470
Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53. 10.1097/QAI.0b013e31821d33a5. DOI: 10.1097/QAI.0b013e31821d33a5
Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781–4. 10.1097/QAD.0b013e32833ad8b4. DOI: 10.1097/QAD.0b013e32833ad8b4
Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Chen R, Scherzer R, Hsue PY, Jotwani V, Estrella MM, Horberg MA, Grunfeld C, Shlipak MG. Association of tenofovir use with risk of incident heart failure in HIV-INFECTED PATIENTS. J Am Heart Assoc. 2017;6(4): e005387. 10.1161/JAHA.116.005387. DOI: 10.1161/JAHA.116.005387
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48. 10.1038/s41572-020-0181-1. DOI: 10.1038/s41572-020-0181-1
Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510–20. 10.1016/S2352-3018(16)30091-1. DOI: 10.1016/S2352-3018(16)30091-1
Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–55. 10.1097/QAI.0b013e3182965d45. DOI: 10.1097/QAI.0b013e3182965d45
Gotham D, Hill A, Pozniak AL. Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. Curr Opin HIV AIDS. 2017;12(4):324–33. 10.1097/COH.0000000000000379. DOI: 10.1097/COH.0000000000000379
Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124(4):479–90. 10.1111/bcpt.13161. DOI: 10.1111/bcpt.13161
Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387–91. 10.1097/QAD.0000000000002350. DOI: 10.1097/QAD.0000000000002350
Bares SH. Is modern antiretroviral therapy causing weight gain? Clin Infect Dis. 2020;71(6):1390–2. 10.1093/cid/ciz1004. DOI: 10.1093/cid/ciz1004
Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, Wester CW, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50–8. 10.1089/aid.2015.0147. DOI: 10.1089/aid.2015.0147
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–89. 10.1093/cid/ciz999. DOI: 10.1093/cid/ciz999
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Dolutegravir plus Two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–15. 10.1056/NEJMoa1902824. DOI: 10.1056/NEJMoa1902824
Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–26. 10.1056/NEJMoa1904340. DOI: 10.1056/NEJMoa1904340
